{"id":5463,"date":"2026-01-13T17:19:42","date_gmt":"2026-01-13T14:19:42","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5463"},"modified":"2026-01-13T17:24:59","modified_gmt":"2026-01-13T14:24:59","slug":"edgewise-therapeutics-shared-its-priorities-for-becker-and-duchenne-muscular-dystrophy-in-2026","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/edgewise-therapeutics-shared-its-priorities-for-becker-and-duchenne-muscular-dystrophy-in-2026\/","title":{"rendered":"Edgewise Therapeutics a partag\u00e9 ses priorit\u00e9s pour la dystrophie musculaire de Becker et de Duchenne en 2026."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Edgewise Therapeutics a fait le point sur les programmes cliniques de la soci\u00e9t\u00e9 (dystrophie musculaire de Becker \/ dystrophie musculaire de Duchenne) et a soulign\u00e9 les principales \u00e9tapes pr\u00e9vues pour 2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Priorit\u00e9s 2026 \u2013 Sevasemten<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;\u00e9tude ach\u00e8vera la cohorte pivotale mondiale GRAND CANYON et annoncera les principaux r\u00e9sultats concernant les personnes atteintes de Becker au quatri\u00e8me trimestre 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nous nous pr\u00e9parerons \u00e0 soumettre une demande d&#039;autorisation de mise sur le march\u00e9 (AMM) aupr\u00e8s de la Food and Drug Administration am\u00e9ricaine pour le sevasemten \u00e0 Becker au cours du premier semestre 2027.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Finaliser la conception et le plan d&#039;un essai de phase 3 chez des personnes atteintes de dystrophie musculaire de Duchenne (Duchenne) au cours du second semestre 2026. <strong>Apprendre encore plus:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/fr\/edgewise-therapeutics-reports-positive-results-on-sevasemten-program-for-becker-and-duchenne-muscular-dystrophies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Qu&#039;est-ce que Sevasemten ?<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">R\u00e9alisations de 2025 pour Duchenne et Becker<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Inscription termin\u00e9e pour les adultes de GRAND CANYON avec Becker.<\/li>\n\n\n\n<li>Des donn\u00e9es pr\u00e9liminaires positives ont \u00e9t\u00e9 rapport\u00e9es \u00e0 partir de l&#039;\u00e9tude d&#039;extension en ouvert de phase 2 MESA chez des adultes atteints de Becker.<\/li>\n\n\n\n<li>Des observations encourageantes ont \u00e9t\u00e9 rapport\u00e9es lors de l&#039;essai contr\u00f4l\u00e9 par placebo de phase 2 LYNX chez des participants atteints de Duchenne sur des mesures fonctionnelles, notamment la vitesse de foul\u00e9e au 95e centile (SV95C), l&#039;\u00e9valuation ambulatoire North Star (NSAA) et la mont\u00e9e de 4 escaliers, tout en identifiant une dose de 10 mg \u00e0 \u00e9valuer en phase 3.<\/li>\n\n\n\n<li>Les premiers r\u00e9sultats rapport\u00e9s de l&#039;essai FOX de phase 2 contr\u00f4l\u00e9 par placebo chez des participants atteints de dystrophie musculaire de Duchenne pr\u00e9alablement trait\u00e9s par th\u00e9rapie g\u00e9nique ont \u00e9galement confirm\u00e9 que le sevasemten 10 mg a le potentiel de r\u00e9duire le taux de d\u00e9clin fonctionnel.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Edgewise Therapeutics provided updates on the Company&#8217;s clinical programs (Becker Muscular Dystrophy \/ Duchenne Muscular Dystrophy) and highlighted major milestones for 2026. 2026 Priorities &#8211; Sevasemten Will complete the GRAND CANYON global pivotal cohort and will announce top-line results in individuals with Becker in the fourth quarter of 2026. Will prepare for submission of a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5464,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[67,66,151,152,150],"class_list":["post-5463","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-becker-muscular-dystrophy","tag-duchenne-muscular-dystrophy","tag-edgewise","tag-edgewise-therapeutics","tag-sevasemten"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=5463"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5463\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/5464"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=5463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=5463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=5463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}